A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BI 3814916 in Healthy Male and Female Subjects
Latest Information Update: 28 Mar 2026
At a glance
- Drugs BI 3814916 (Primary)
- Indications Unspecified
- Focus First in man; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 25 Mar 2026 New trial record